To the Editor: We really appreciated the interest and comments by Rigalleau and colleagues on our recent article [1] . We agree that the proportion of individuals with the nonalbuminuric (Alb − ) phenotype with type 1 diabetes and chronic kidney disease (CKD) in our study was surprisingly high (17 out of 29, 58.6%) [2] . This figure is higher than that reported by Thorn et al [3] in the FinnDiane Study (78 out of 502, 15.5%; p < 0.0001, χ 2 test) and, also, in the DCCT/Epidemiology of Diabetes Interventions and Complications (EDIC) Study [4] , in which 23.6% of individuals (21 out of 89; p < 0.001, χ 2 test) were reported as having normoalbuminuria (albumin excretion rate [AER] ≤ 30 mg/ 24 h) and estimated GFR (eGFR) < 60 ml min
. Nonetheless, our figure is similar to the one reported in the Renal Insufficiency And Cardiovascular Events (RIACE) Study [5] , which enrolled a large cohort of Italian individuals with type 2 diabetes and found that 1673 out of 2959 (56.5%) individuals with eGFR < 60 ml min −1 [1.73 m] −2 had normoalbuminuria. The reasons for these discrepancies are not readily apparent. Whether local pathogenic background and clinical management could contribute to these differences is a hypothesis that needs to be verified. Rigalleau et al claim that our results may be overestimated by the assessment of glomerular filtration rate by the Modification of Diet in Renal Disease (MDRD) Study equation. Though we are fully aware of the limitations of this equation, this is unlikely to account for the observed discrepancies as the same approach was used in the DCCT/EDIC survey [4] . Moreover, as reported in the supplementary material of our study (ESM Table 5 . Furthermore, a less advanced renal failure has been consistently reported in those with CKD and the Alb − phenotype compared with the Alb + phenotype in the RIACE Study [5] . It is well known that the MDRD equation can underestimate GFR, as compared with measured GFR (mGFR), particularly in the normal to high range [7] . The CKD-EPI equation also appears to underestimate normal to high GFR to a similar extent as the MDRD equation in people with diabetes [8] . Whether MDRD equation-eGFR underestimation also occurs in individuals with stage 3 CKD is a matter of debate [9] . MacIsaac et al [8] suggest that the precision of GFR estimates by the MDRD and CKD-EPI equations improves with lower GFR values; in their study, in 60 participants with mGFR < 60 ml min . Moreover, estimation of GFR by the CKD-EPI equation instead of the MDRD equation did not change the conclusions and the overall results presented in our paper [2] . In more detail, CKD-EPI equation-derived eGFR was 55.6 ± 8.1 ml min , 16 and 2 were reclassified as having a higher eGFR using the CKD-EPI equation, respectively. However, even taking this into account did not affect results and conclusions of our analysis.
We agree with Rigalleau et al that relatively higher eGFR in individuals with the Alb − phenotype and stage ≥3 CKD may reflect a slower rate of deterioration of renal function with reduced progression to end-stage renal disease (ESRD). Since we did not measure this outcome, data from our study cannot prove or disprove this theory. However, the hypothesis is supported by data reported by Rigalleu et al in a 3 year follow-up of their study [11] and by the FinnDiane's longer 13 year follow-up [3] . In the second Joslin Kidney Study, the prevalence of 'decliners' (those with renal decline ≥3.3% per year) was 10% in In summary, given the many limitations of estimating vs measuring GFR, we believe our data are consistent with a growing literature showing a progressive increase of the prevalence of the non-albuminuric CKD phenotype. Since equations are commonly used in the clinical setting, it is important for physicians to appreciate the existence of such a phenotype and its implications in stratifying renal and cardiovascular risk.
